Cargando…
Carbon ion therapy (C12) for high-grade malignant salivary gland tumors (MSGTs) of the head and neck: do non-ACCs profit from dose escalation?
PURPOSE: To evaluate the use of high-dose radiotherapy using carbon ions (C12) on non-adenoid cystic malignant salivary gland tumors (MSGT). PATIENTS AND METHODS: Between 2009 and 2013, patients with biopsy-proven non-ACC MSGT histologies of the head and neck received a combined regimen of IMRT plus...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936021/ https://www.ncbi.nlm.nih.gov/pubmed/27386864 http://dx.doi.org/10.1186/s13014-016-0657-z |
_version_ | 1782441502767579136 |
---|---|
author | Jensen, A. D. Poulakis, M. Vanoni, V. Uhl, M. Chaudhri, N. Federspil, P. A. Freier, K. Krauss, J. Debus, J. |
author_facet | Jensen, A. D. Poulakis, M. Vanoni, V. Uhl, M. Chaudhri, N. Federspil, P. A. Freier, K. Krauss, J. Debus, J. |
author_sort | Jensen, A. D. |
collection | PubMed |
description | PURPOSE: To evaluate the use of high-dose radiotherapy using carbon ions (C12) on non-adenoid cystic malignant salivary gland tumors (MSGT). PATIENTS AND METHODS: Between 2009 and 2013, patients with biopsy-proven non-ACC MSGT histologies of the head and neck received a combined regimen of IMRT plus C12 boost. Treatment toxicity (CTC v3), response (RECIST 1.1), control and survival rates were retrospectively analyzed. RESULTS: 40 patients with pathologically confirmed non-ACC MSGT (T4: 45 %; N+: 40 %; gross residual: 58 %; mucoepidermoid carcinoma (MEC): 45 %; adenocarcinoma: 20 %) were treated with a median of 74 GyE (80 Gy BED). Chemoradiation was given in 5 patients with MEC. Grade III acute toxicity was observed in up to 15 % (mucositis, dermatitis, dysphagia), no higher-grade late toxicity occurred to date. At a follow-up of 25.5 months, LC, and PFS at 2 and 3 years are 81.5 % (LC) and 66.8 % (PFS), OS at 2 and 3 years is 83.6 % and 72.8 %. Most frequent site of disease progression was distant metastasis. Histologic subtype correlated with LC and PFS. Resection status (gross vs microscopic disease) had no significant effect on LC, PFS, or OS. CONCLUSION: The treatment is well tolerated, no higher grade late effects were observed. Considering the negative pre-selection, LC, PFS and OS are promising. While histology and site of origin significantly influenced control and survival rates, resection status did not, potentially due to the effect of dose escalation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13014-016-0657-z) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4936021 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-49360212016-07-07 Carbon ion therapy (C12) for high-grade malignant salivary gland tumors (MSGTs) of the head and neck: do non-ACCs profit from dose escalation? Jensen, A. D. Poulakis, M. Vanoni, V. Uhl, M. Chaudhri, N. Federspil, P. A. Freier, K. Krauss, J. Debus, J. Radiat Oncol Research PURPOSE: To evaluate the use of high-dose radiotherapy using carbon ions (C12) on non-adenoid cystic malignant salivary gland tumors (MSGT). PATIENTS AND METHODS: Between 2009 and 2013, patients with biopsy-proven non-ACC MSGT histologies of the head and neck received a combined regimen of IMRT plus C12 boost. Treatment toxicity (CTC v3), response (RECIST 1.1), control and survival rates were retrospectively analyzed. RESULTS: 40 patients with pathologically confirmed non-ACC MSGT (T4: 45 %; N+: 40 %; gross residual: 58 %; mucoepidermoid carcinoma (MEC): 45 %; adenocarcinoma: 20 %) were treated with a median of 74 GyE (80 Gy BED). Chemoradiation was given in 5 patients with MEC. Grade III acute toxicity was observed in up to 15 % (mucositis, dermatitis, dysphagia), no higher-grade late toxicity occurred to date. At a follow-up of 25.5 months, LC, and PFS at 2 and 3 years are 81.5 % (LC) and 66.8 % (PFS), OS at 2 and 3 years is 83.6 % and 72.8 %. Most frequent site of disease progression was distant metastasis. Histologic subtype correlated with LC and PFS. Resection status (gross vs microscopic disease) had no significant effect on LC, PFS, or OS. CONCLUSION: The treatment is well tolerated, no higher grade late effects were observed. Considering the negative pre-selection, LC, PFS and OS are promising. While histology and site of origin significantly influenced control and survival rates, resection status did not, potentially due to the effect of dose escalation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13014-016-0657-z) contains supplementary material, which is available to authorized users. BioMed Central 2016-07-07 /pmc/articles/PMC4936021/ /pubmed/27386864 http://dx.doi.org/10.1186/s13014-016-0657-z Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Jensen, A. D. Poulakis, M. Vanoni, V. Uhl, M. Chaudhri, N. Federspil, P. A. Freier, K. Krauss, J. Debus, J. Carbon ion therapy (C12) for high-grade malignant salivary gland tumors (MSGTs) of the head and neck: do non-ACCs profit from dose escalation? |
title | Carbon ion therapy (C12) for high-grade malignant salivary gland tumors (MSGTs) of the head and neck: do non-ACCs profit from dose escalation? |
title_full | Carbon ion therapy (C12) for high-grade malignant salivary gland tumors (MSGTs) of the head and neck: do non-ACCs profit from dose escalation? |
title_fullStr | Carbon ion therapy (C12) for high-grade malignant salivary gland tumors (MSGTs) of the head and neck: do non-ACCs profit from dose escalation? |
title_full_unstemmed | Carbon ion therapy (C12) for high-grade malignant salivary gland tumors (MSGTs) of the head and neck: do non-ACCs profit from dose escalation? |
title_short | Carbon ion therapy (C12) for high-grade malignant salivary gland tumors (MSGTs) of the head and neck: do non-ACCs profit from dose escalation? |
title_sort | carbon ion therapy (c12) for high-grade malignant salivary gland tumors (msgts) of the head and neck: do non-accs profit from dose escalation? |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936021/ https://www.ncbi.nlm.nih.gov/pubmed/27386864 http://dx.doi.org/10.1186/s13014-016-0657-z |
work_keys_str_mv | AT jensenad carboniontherapyc12forhighgrademalignantsalivaryglandtumorsmsgtsoftheheadandneckdononaccsprofitfromdoseescalation AT poulakism carboniontherapyc12forhighgrademalignantsalivaryglandtumorsmsgtsoftheheadandneckdononaccsprofitfromdoseescalation AT vanoniv carboniontherapyc12forhighgrademalignantsalivaryglandtumorsmsgtsoftheheadandneckdononaccsprofitfromdoseescalation AT uhlm carboniontherapyc12forhighgrademalignantsalivaryglandtumorsmsgtsoftheheadandneckdononaccsprofitfromdoseescalation AT chaudhrin carboniontherapyc12forhighgrademalignantsalivaryglandtumorsmsgtsoftheheadandneckdononaccsprofitfromdoseescalation AT federspilpa carboniontherapyc12forhighgrademalignantsalivaryglandtumorsmsgtsoftheheadandneckdononaccsprofitfromdoseescalation AT freierk carboniontherapyc12forhighgrademalignantsalivaryglandtumorsmsgtsoftheheadandneckdononaccsprofitfromdoseescalation AT kraussj carboniontherapyc12forhighgrademalignantsalivaryglandtumorsmsgtsoftheheadandneckdononaccsprofitfromdoseescalation AT debusj carboniontherapyc12forhighgrademalignantsalivaryglandtumorsmsgtsoftheheadandneckdononaccsprofitfromdoseescalation |